Cargando…
Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years
The observational CERTITUDE study follows liver transplant patients who completed the SIMCER trial. SIMCER randomized patients at month 1 after transplant to everolimus (EVR) with stepwise tacrolimus (TAC) withdrawal or to standard TAC, both with basiliximab induction and mycophenolic acid ± steroid...
Autores principales: | Saliba, Faouzi, Duvoux, Christophe, Dharancy, Sébastien, Dumortier, Jérôme, Calmus, Yvon, Gugenheim, Jean, Kamar, Nassim, Salamé, Ephrem, Neau‐Cransac, Martine, Vanlemmens, Claire, Durand, François, Pageaux, Georges, Leroy, Vincent, Hardwigsen, Jean, Gharbi, Hakam, Masson, Cécile, Tindel, Malka, Conti, Filomena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383505/ https://www.ncbi.nlm.nih.gov/pubmed/31631501 http://dx.doi.org/10.1002/lt.25664 |
Ejemplares similares
-
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
por: Saliba, Faouzi, et al.
Publicado: (2022) -
Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022) -
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis
por: Villeret, François, et al.
Publicado: (2023) -
Influenza and SARS-CoV-2 vaccinations adherence after liver transplantation during the second year of the COVID-19 pandemic (results of a patients’ survey)
por: Dumortier, Jérôme, et al.
Publicado: (2022) -
Influenza vaccination adherence after liver transplantation: A collateral benefit of the COVID-19 pandemic (results of a patients’ survey)
por: Dumortier, Jérôme, et al.
Publicado: (2022)